<DOC>
	<DOCNO>NCT02735057</DOCNO>
	<brief_summary>Management elderly patient cancer therapeutic challenge public health problem . The mean age esophageal cancer 64.5 year 72.1 year men woman respectively . Surgery standard treatment reserve 30 % patient . The 70 % consider unfit surgery various reason , include age . Chemoradiotherapy ( CRT ) standard treatment patient esophageal cancer unfit surgery . The validated treatment scheme external beam radiotherapy ( EBRT ) 50 Gy 5 week combine cisplatin 5FU infusion . However induce high rate severe life threaten toxicity : grade 3 haematologic esophageal mucositis 20 25 % respectively , patient median age 64 year . CRT properly evaluate patient 75 year , combine chemotherapy challenging .</brief_summary>
	<brief_title>Chemoradiotherapy Elderly Patients With Oesophagus Cancer</brief_title>
	<detailed_description>Choice combine chemotherapy Carboplatin taxanes deliver concurrently radiotherapy attractive . A Dutch randomized study ( Cross trial ) compare preoperative CRT surgery 368 patient T1-T3 N0N1 . In preoperative CRT group , patient receive 41.4 Gy EBRT 5 week combine carboplatin ( AUC 2 ) paclitaxel ( 50 mg/m2 ) . A 30 % tumor sterilization rate reduction metastasis consider distant effect chemotherapy observe . The 5-year survival statistically well CRT group . The preoperative CRT well tolerate acute toxicity observe . Intriguingly , French randomize study , conduct less locally advanced disease , combination 45 Gy 5 FU infusion Cisplatin induce tumor sterilization rate , suggest carboplatine/paclitaxel effective 5FU/cisplatin CRT . Study design Since optimal dos component radiotherapy- carboplatin - paclitaxel unknown , plan conduct phase I/II study - Phase I : objective determine maximum tolerate dose ( MTD ) recommend dos phase II ( RP2D ) component consider treatment scheme Dutch study reference : - chemotherapy 3 level : 50 % , 75 % 100 % standard Dutch dose ( carboplatin AUC 2 paclitaxel 50 mg/m2 ) - radiotherapy 3 level : 41.4 Gy/1.8 Gy/f ; 45 Gy/1.8 Gy/f ; 50.4 Gy/1.8 Gy/f basel level : 41.4 Gy 50 % standard CT dose The phase I conduct increase dos component 9 level . - Phase II : determination RP2D component , study continue phase II order ass tumor response Secondary objective : Quality life , progression free overall survival</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Esophageal cancer , squamous adenocarcinoma type , T13 , N01 , M1a ( TNM 6th ) , age &gt; 75 year , WHO status &lt; 2 , Balducci 1 , adequate bone marrow reserve , normal renal hepatic function . age &lt; 75 year</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>oesophagus cancer</keyword>
</DOC>